vs
伯乐实验室（BIO）与帕可Bio（PACB）财务数据对比。点击上方公司名可切换其他公司
伯乐实验室的季度营收约是帕可Bio的15.5倍（$693.2M vs $44.6M）。伯乐实验室净利率更高（103.9% vs -90.4%，领先194.3%）。帕可Bio同比增速更快（13.8% vs 3.9%）。伯乐实验室自由现金流更多（$119.1M vs $-19.9M）。过去两年帕可Bio的营收复合增速更高（7.3% vs 6.5%）
美国伯乐实验室是深耕生命科学研究与临床诊断领域的专业技术产品开发商及制造商，1952年由加州大学伯克利分校校友施瓦茨夫妇在伯克利创立，总部位于加州赫拉克勒斯，业务网络覆盖全球。
太平洋生物科学（加利福尼亚）公司是2004年成立的美国生物技术企业，专注于研发生产基因测序相关设备，还可实现新型实时生物观测。公司拥有两大核心测序平台：基于零模波导特性的单分子实时测序平台（SMRT），以及采用天然核苷酸、无损伤掺入完成DNA结合与延伸的结合测序技术（SBB）平台。
BIO vs PACB — 直观对比
营收规模更大
BIO
是对方的15.5倍
$44.6M
营收增速更快
PACB
高出10.0%
3.9%
净利率更高
BIO
高出194.3%
-90.4%
自由现金流更多
BIO
多$139.0M
$-19.9M
两年增速更快
PACB
近两年复合增速
6.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $693.2M | $44.6M |
| 净利润 | $720.0M | $-40.4M |
| 毛利率 | 49.8% | 37.1% |
| 营业利润率 | -17.2% | -92.3% |
| 净利率 | 103.9% | -90.4% |
| 营收同比 | 3.9% | 13.8% |
| 净利润同比 | 200.6% | -1802.7% |
| 每股收益（稀释后） | $26.59 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOPACB
| Q4 25 | $693.2M | $44.6M | ||
| Q3 25 | $653.0M | $38.4M | ||
| Q2 25 | $651.6M | $39.8M | ||
| Q1 25 | $585.4M | $37.2M | ||
| Q4 24 | $667.5M | $39.2M | ||
| Q3 24 | $649.7M | $40.0M | ||
| Q2 24 | $638.5M | $36.0M | ||
| Q1 24 | $610.8M | $38.8M |
净利润BIOPACB
| Q4 25 | $720.0M | $-40.4M | ||
| Q3 25 | $-341.9M | $-38.0M | ||
| Q2 25 | $317.8M | $-41.9M | ||
| Q1 25 | $64.0M | $-426.1M | ||
| Q4 24 | $-715.8M | $2.4M | ||
| Q3 24 | $653.2M | $-60.7M | ||
| Q2 24 | $-2.2B | $-173.3M | ||
| Q1 24 | $383.9M | $-78.2M |
毛利率BIOPACB
| Q4 25 | 49.8% | 37.1% | ||
| Q3 25 | 52.6% | 41.4% | ||
| Q2 25 | 53.0% | 36.9% | ||
| Q1 25 | 52.3% | -3.7% | ||
| Q4 24 | 51.2% | 25.6% | ||
| Q3 24 | 54.8% | 25.0% | ||
| Q2 24 | 55.6% | 16.5% | ||
| Q1 24 | 53.4% | 29.1% |
营业利润率BIOPACB
| Q4 25 | -17.2% | -92.3% | ||
| Q3 25 | 10.0% | -101.1% | ||
| Q2 25 | 11.8% | -112.8% | ||
| Q1 25 | 4.0% | -1154.5% | ||
| Q4 24 | 8.7% | -390.1% | ||
| Q3 24 | 9.9% | -160.3% | ||
| Q2 24 | 15.9% | -488.3% | ||
| Q1 24 | 7.3% | -209.6% |
净利率BIOPACB
| Q4 25 | 103.9% | -90.4% | ||
| Q3 25 | -52.4% | -98.9% | ||
| Q2 25 | 48.8% | -105.4% | ||
| Q1 25 | 10.9% | -1146.8% | ||
| Q4 24 | -107.2% | 6.0% | ||
| Q3 24 | 100.5% | -151.9% | ||
| Q2 24 | -339.2% | -481.3% | ||
| Q1 24 | 62.9% | -201.4% |
每股收益（稀释后）BIOPACB
| Q4 25 | $26.59 | $-0.11 | ||
| Q3 25 | $-12.70 | $-0.13 | ||
| Q2 25 | $11.67 | $-0.14 | ||
| Q1 25 | $2.29 | $-1.44 | ||
| Q4 24 | $-25.89 | $-0.44 | ||
| Q3 24 | $23.34 | $-0.22 | ||
| Q2 24 | $-76.26 | $-0.64 | ||
| Q1 24 | $13.45 | $-0.29 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.5B | $279.5M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $7.5B | $5.3M |
| 总资产 | $10.6B | $784.1M |
| 负债/权益比越低杠杆越低 | 0.16× | — |
8季度趋势，按日历期对齐
现金及短期投资BIOPACB
| Q4 25 | $1.5B | $279.5M | ||
| Q3 25 | $1.4B | $298.7M | ||
| Q2 25 | $1.4B | $314.7M | ||
| Q1 25 | $1.7B | $343.1M | ||
| Q4 24 | $1.7B | $389.9M | ||
| Q3 24 | $1.6B | $471.1M | ||
| Q2 24 | $1.6B | $509.8M | ||
| Q1 24 | $1.6B | $561.9M |
总债务BIOPACB
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BIOPACB
| Q4 25 | $7.5B | $5.3M | ||
| Q3 25 | $6.7B | $36.1M | ||
| Q2 25 | $7.1B | $61.5M | ||
| Q1 25 | $6.7B | $91.6M | ||
| Q4 24 | $6.6B | $506.6M | ||
| Q3 24 | $7.5B | $453.1M | ||
| Q2 24 | $6.8B | $492.7M | ||
| Q1 24 | $9.1B | $649.0M |
总资产BIOPACB
| Q4 25 | $10.6B | $784.1M | ||
| Q3 25 | $9.7B | $803.2M | ||
| Q2 25 | $10.2B | $825.5M | ||
| Q1 25 | $9.5B | $860.8M | ||
| Q4 24 | $9.4B | $1.3B | ||
| Q3 24 | $10.6B | $1.5B | ||
| Q2 24 | $9.7B | $1.5B | ||
| Q1 24 | $12.6B | $1.7B |
负债/权益比BIOPACB
| Q4 25 | 0.16× | — | ||
| Q3 25 | 0.18× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.9M | $-19.1M |
| 自由现金流经营现金流 - 资本支出 | $119.1M | $-19.9M |
| 自由现金流率自由现金流/营收 | 17.2% | -44.6% |
| 资本支出强度资本支出/营收 | 6.6% | 1.9% |
| 现金转化率经营现金流/净利润 | 0.23× | — |
| 过去12个月自由现金流最近4个季度 | $374.6M | $-114.1M |
8季度趋势，按日历期对齐
经营现金流BIOPACB
| Q4 25 | $164.9M | $-19.1M | ||
| Q3 25 | $120.9M | $-18.7M | ||
| Q2 25 | $116.5M | $-29.4M | ||
| Q1 25 | $129.9M | $-44.1M | ||
| Q4 24 | $124.2M | $-30.6M | ||
| Q3 24 | $163.6M | $-45.5M | ||
| Q2 24 | $97.6M | $-54.3M | ||
| Q1 24 | $69.8M | $-75.7M |
自由现金流BIOPACB
| Q4 25 | $119.1M | $-19.9M | ||
| Q3 25 | $89.2M | $-18.8M | ||
| Q2 25 | $70.8M | $-29.9M | ||
| Q1 25 | $95.5M | $-45.4M | ||
| Q4 24 | $81.2M | $-32.3M | ||
| Q3 24 | $123.4M | $-46.3M | ||
| Q2 24 | $55.4M | $-55.7M | ||
| Q1 24 | $29.6M | $-79.6M |
自由现金流率BIOPACB
| Q4 25 | 17.2% | -44.6% | ||
| Q3 25 | 13.7% | -48.9% | ||
| Q2 25 | 10.9% | -75.3% | ||
| Q1 25 | 16.3% | -122.3% | ||
| Q4 24 | 12.2% | -82.3% | ||
| Q3 24 | 19.0% | -115.7% | ||
| Q2 24 | 8.7% | -154.8% | ||
| Q1 24 | 4.8% | -205.0% |
资本支出强度BIOPACB
| Q4 25 | 6.6% | 1.9% | ||
| Q3 25 | 4.9% | 0.2% | ||
| Q2 25 | 7.0% | 1.4% | ||
| Q1 25 | 5.9% | 3.7% | ||
| Q4 24 | 6.4% | 4.1% | ||
| Q3 24 | 6.2% | 2.0% | ||
| Q2 24 | 6.6% | 4.1% | ||
| Q1 24 | 6.6% | 10.0% |
现金转化率BIOPACB
| Q4 25 | 0.23× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.37× | — | ||
| Q1 25 | 2.03× | — | ||
| Q4 24 | — | -12.93× | ||
| Q3 24 | 0.25× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
PACB
| Products | $39.0M | 87% |
| Service And Other | $5.7M | 13% |
